Cipla Partners With Bio-Thera For Bevacizumab In Select Emerging Markets

 
• By Grace Montgomery

Cipla has formed a licensing agreement with Bio-Thera Solutions for the Chinese firm’s BAT1706 bevacizumab biosimilar, which the Indian company will distribute and sell in select emerging markets.

AbstractHandshake
Cipla forms deal with Bio-Thera for bevacizumab in select emerging markets • Source: Shutterstock

More from Biosimilars

More from Products